Adolescents and young adults (AYA) surviving classical Hodgkin lymphoma (cHL) risk long term fatal treatment-related toxicities. We utilized the Surveillance, Epidemiology and End Results (SEER) program to compare excess mortality rate (EMR-observed minus expected mortality) for 10-year survivors of AYA cHL diagnosed in 1973-1992 and 1993-2003 eras. The 15-year EMR reduced from 4.88% to 2.19% while the 20-year EMR reduced from 9.46% to 4.07% between eras. Survivors of stages 1-2 had lower EMR than survivors of stages 3-4 cHL in the [1993][1994][1995][1996][1997][1998][1999][2000][2001][2002][2003] but not in the 1973-1992 era. There was an overall decline in risk of death between 10 and 15 years from diagnosis, driven mostly by second neoplasms and cardiovascular mortality. Despite reduction in fatal second neoplasms and cardiovascular disease with more current therapy, long term survivors of AYA cHL still have a higher risk of death than the general population highlighting the need for safer therapies.
| I N TR ODU C TI ON
Adolescents and young adults (AYA) constitute the majority of patients with classical Hodgkin lymphoma (cHL), and most of those patients will be cured with multi-agent chemotherapy or combined used of chemotherapy and radiation therapy. 1 However, this therapeutic success has been hindered by the development of significant treatment-related late toxicities. 2, 3 In addition to having a high risk of developing second malignant neoplasms (SMN), cHL survivors face a variety of chronic medical conditions linked to cancer therapy. 4 Treatment-induced chronic illness and SMN contribute to premature deaths among cHL survivors. 5 Successive generations of cHL therapy over the past several decades have modified the long term risk and toxicity profile of survivors.
The early 1990s marks the transition between use of higher dose, extended-field radiation, and MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) chemotherapy 6 to lower doses, involved-field radiation, and ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) regimen as more common approaches to treat patients with cHL. 7 More recently, both pediatric and adult studies have focused on early risk stratification and response-adapted therapy to tailor treatment strategies. 8 Those approaches have led to further improvement in survival rates and risk reduction of therapy related long-term toxicities as exemplified in a large cohort of pediatric cHL survivors. 9 The increased risk of death in long-term survivors and the temporal trends in such risk have not been well characterized at the population level, particularly in young adults. In this study, we utilized a large population-based data set focusing on AYA cHL survivors to better understand and compare excess mortality in 2 consecutive eras. We aimed to evaluate possible factors associated with late excess mortality, and described and compared causes of death among 10-year survivors of AYA cHL across different time periods. We included all patients between the ages of 15-39 years at the time of cHL diagnosis. We identified cHL cases using the third edition of the 
| M E TH ODS

| Data analysis and statistics
We described the population included utilizing the case listing session function of SEER*Stat Version 8.3.2. We obtained actual and expected survival at time points of interest utilizing the survival function in SEER*Stat using the US census of 2000 as reference. Since the study addresses exclusively 10-year survivors, actual and expected mortality were adjusted to 0% at 10 years for the cohorts being studied. The main parameter studied was EMR, which is, the difference between the observed mortality rate in the cohort being studied and the expected mortality rate in a contemporaneous population of similar age, gender, and race/ethnicity structure. Along with relative survival, EMR is a possible approach to compare observed and expected survival (or mortality) of a cohort. EMR is defined as "the death rate in the general population due to the excess risk imposed by specific disease". 10 We chose to use EMR as it provides a more direct and intuitive way to Comparisons between rates were performed using Z-test. We performed statistical analysis using SPSS (IBM Corp. Released 2013.
IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY). Statistical tests were 2-sided and considered significant when P < .05.
| RE S U L TS
3.1 | Population Table 1 respectively. These results were found to be significantly higher in comparison to survivors of localized stage cHL at 15-(1.69%, 95% C.I
| Excess mortality
1.19%-2.44%, P 5 .007) and at 20-year (2.57%, 95% C.I. 1.81%-4.09%, P 5 .03) EMR treated in the same era ( Figure 2D) . Similarly, for patients treated in the most recent era, there was higher EMR among male survivors in comparison to females at 15-years post-treatment (2.98%, 95% C.I. 2.15%-4.08% for males vs. 1.59%, 95% C.I.
1.05%-2.47% for females, P 5 .02) ( Figure 2E ). We found no significant difference in EMR between localized-stage patients treated with or without radiation therapy in the 1993-2003 cohort ( Figure 2F ).
| Causes of death
Although it is not possible to attribute the cause of excess mortality without information on expected COD in the general population, we analyzed overall COD at years 10 and 15 from diagnosis as a window into the factors possibly implicated in excess risk of death. There were For the 1993-1997 sub-cohort, there were 67 deaths among 2196 patients followed for a total of 10 615.6 person-years.
The SMN was the leading cause of death among patients in the 1983-1987 sub-cohort, while cHL was the leading cause of the death in the more recent sub-cohort (Table 2 ). There was an overall decline in risk of death between the 2 eras, driven mostly by a reduction in risk of death from SMN and cardiovascular causes. The reduction in death from cHL among 10-year survivors did not reach statistical significance.
The reduction in risk of death in years 10-15 for 10-year survivors seems to span across both genders and it was far more pronounced among patients with localized cHL where there was substantial reduction in risk of death from any cause (11.7 to 4.5 deaths/1000 personyear, P < .0001), from SMN (3.2 to 1.1 deaths/1000 person-year, P 5 .012) and from cardiovascular causes (2.8 to 0.4 deaths/1000
person-year, P < .0001), but not from cHL (2.1 to 1.1 deaths/1000
person-year, P 5 .16), as shown in The total of the 2 stage categories is less than the total number of patients due to missing stage in some cases. 
| D I SCUSSION
Using a large population-based data set, the present study verified that despite significant improvements in treatment and cure rates in the most recent years, long-term survivors of AYA cHL continue to have a higher risk of death than matched population. Our findings are of crucial importance since cHL predominantly affects AYA, individuals who otherwise would have a long life expectancy. As the cohort ages, some deaths are expected, as in the matched population, making it important to use the expected mortality in the population as reference. Therefore, using EMR allows us to determine the impact of having cHL and/or receiving cHL therapy on the long-term risk of death. were broadly used only after 2000. 21 In addition to modifications in radiation therapy fields and doses, reduction in risk of SMN could have resulted from minimum exposure or complete elimination of nitrogen mustard from HL treatment regimens in the 1990s. 22, 23 We found reduction in deaths from SMN among survivors of localized cHL but not among survivors of advanced cHL (Table 2) , reinforcing the hypothesis that de-intensification of therapy in localized cHL is linked to reduction in risk of fatal SMN.
We observed a decline in the risk of death due to cardiovascular diseases between the 2 eras ( Table 2 ). We also found higher late EMR among male survivors in comparison to females across eras. It is possible that this finding correlates in part with the fact that cardiovascular diseases appear to disproportionally affect late mortality among males.
Mechanisms of cardiovascular toxicity among cHL survivors are complex, multifactorial, and persist throughout life. [24] [25] [26] [27] Hypertension, smoking, hypercholesterolemia, and diabetes are also more prevalent among men. These factors seem to further accentuate the risk of cardiovascular complications among cHL survivors that is usually driven by radiation therapy and anthracycline exposure. 20, [28] [29] [30] It is possible that reduction in deaths from cardiovascular disease reflects both improved safety of therapy and better control of risk factors, including smoking cessation.
Our study is met by some limitations. It is believed that the vast majority of patients included in this cohort would have received chemotherapy or combined modality therapy. This information, however, is not available in the SEER registry. Therefore, the association between therapeutic interventions and possible outcomes should be interpreted as hypothesis generating. Additionally, since we do not have information on COD in the general population using the same criteria utilized for COD assignment in SEER, it is not possible to estimate which components of late mortality are attributable to cHL and its treatment.
However, it is reasonable to assume that the majority of the deaths,
